Loading…
Loading…
KAYS does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for KAYS and 80,000+ other tickers.
See exactly how KAYS's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for KAYS and 80,000+ other tickers.
Kaya Holdings, Inc. operates as a comprehensive, vertically integrated entity within the regulated cannabis industry, engaging in the cultivation, processing, distribution, and retail of a wide spectrum of cannabis products across the United States. Its product portfolio encompasses traditional cannabis flower, concentrated oils, vape cartridges, and a range of cannabis-infused edibles, such as confections, baked goods, and beverages. The company manages two proprietary retail outlets known as Kaya Shack. It also features distinct product lines, including strain-specific cannabis cigarettes…
RealReal (NASDAQ: REAL - Get Free Report) and Kaya (OTCMKTS:KAYS - Get Free Report) are both small-cap consumer discretionary companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends. Earnings and Valuation This table compares RealReal and
Spectrum Brands (NYSE: SPB - Get Free Report) and Kaya (OTCMKTS:KAYS - Get Free Report) are both small-cap consumer discretionary companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations. Earnings and Valuation This table compares Spectrum
Valuation and Earnings This table compares Pigeon and Kaya"s gross revenue, earnings per share (EPS) and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pigeon $688.99 million 1.94 $55.26 million $0.13 21.54 Kaya $10,000.00 176.67 -$2.08 million ($0.20) -0.21 Pigeon has higher revenue and earnings than Kaya. Kaya is trading at
NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals, Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as Chief Commercial Officer. Ms. Pai Panandiker is a seasoned commercial and operating leader with more than 20 years of global biopharmaceutical experience, including extensive leadership in neuroscience commercialization and in launching and scaling global brands.
FT. LAUDERDALE, FL / ACCESS Newswire / October 21, 2025 / Kaya Holdings, Inc. (OTCQB:KAYS) (the "Company" or "KAYS") confirmed that its newly formed cryptocurrency operating subsidiary is conducting ongoing discussions with cryptocurrency foundations and other entities/individuals through its representatives Thomas Gaffney of Conduit Advisors ("Thomas") and the team at Greentree Financial Group ("Greentree") to develop a strategy for becoming a Digital Asset Treasury Company ("DATCO"). Thomas is a seasoned corporate attorney and capital markets strategist with extensive experience in the digital asset sector and has worked on billion-dollar transactions with leading venture firms in the crypto space, including Polychain Capital, VanEck, Frictionless Capital, EV3, and others.